Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYS228 in complicated intra-abdominal infection
2017-003130-90Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2018
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ancremonam in Intra-abdominal infection (IAI) (2 arms), sponsored by Novartis. Primary endpoint: Clinical success at Day 28. Started Mar 2018; status: terminated.
02
Drugs
ancremonam
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on 2017-003130-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003130-90.